GSM thins vaginal tissue, reduces lubrication, and makes intercourse painful. It does not resolve on its own — it worsens without treatment. Non-hormonal options (Revaree, Replens) and local vaginal estrogen have strong evidence. Libido loss is driven by testosterone decline, pain avoidance, sleep deprivation, and emotional distance — all addressable. This article contains 3 affiliate links.
Let me tell you something I hear from women constantly — and almost never in the first conversation.
Sex started to hurt. Or it stopped feeling like anything at all. Or they simply stopped wanting it, and then they stopped thinking about it, and then they started quietly avoiding any situation where it might come up. Not because they didn’t love their partner. Not because anything was wrong with their marriage. But because their body had changed in ways nobody warned them about, and the silence around it felt easier than the explanation.
I’m here to break that silence. Not because it’s easy to talk about — but because staying quiet is costing you more than you know.
If you are in perimenopause or menopause and your sex life looks nothing like it did five years ago, you are not broken. You are experiencing the downstream effects of estrogen withdrawal on tissue, neurotransmitters, and the relational context that makes intimacy possible. Every one of those mechanisms is addressable. But the first step is understanding what is actually happening — and that is what this article is for.
What GSM Actually Is — and Why It Gets Worse, Not Better
Genitourinary Syndrome of Menopause is the medical term for the collection of genital, urinary, and sexual symptoms produced by estrogen withdrawal in the lower urogenital tract. It includes vaginal dryness, tissue thinning, reduced lubrication, painful intercourse, urinary urgency, frequency, and increased UTI susceptibility.
Unlike hot flashes and mood changes, which can improve in postmenopause as hormonal levels stabilize at a new baseline, GSM does not improve with time. It is progressive: without treatment, it worsens. Approximately 50 to 70 percent of postmenopausal women experience GSM symptoms. A cross-sectional study of 254 postmenopausal women found that 67.7% reported menopause had a negative impact on their sexual life.
The mechanism is specific. Estrogen maintains the thickness, elasticity, and moisture of vaginal tissue. It supports the lactobacillus population that maintains an acidic vaginal pH. It promotes blood flow to the urogenital tract. When estrogen declines, every one of these systems is affected — tissue thins, lubrication decreases, pH rises (making tissue more fragile and infection-prone), and the elasticity of the vestibular tissue at the vaginal opening decreases.
This is not “dryness.” It is tissue-level atrophy — and the word matters because it shapes the treatment conversation. A lubricant used during sex addresses friction. It does not address the underlying tissue change. And it is the tissue change that makes this progressive.
The Silence That Makes Everything Worse
Most women do not tell their doctors about painful sex. Most doctors do not ask. The result is a clinical gap so wide that the majority of women with GSM go untreated for years — during which the condition worsens and the secondary consequences (relationship strain, sexual avoidance, self-blame, partner misunderstanding) compound.
Partners misread the avoidance as rejection. Women internalize the shame. The 10-minute appointment does not leave room for a conversation that requires vulnerability. And so the information exists, the treatments exist, but the conversation never happens.
What Actually Helps: The Treatment Landscape
This is the section most women came here for — and I am going to give it to you without minimizing anything and without overpromising. Every option below has evidence behind it. Most work remarkably well when used correctly and consistently.
Non-Hormonal Topical · First Line for Dryness
Vaginal Moisturizers and Lubricants
These are two different things, and the distinction matters. Lubricants are used during sexual activity to reduce friction. Moisturizers are used regularly — several times per week — to restore moisture to vaginal tissue over time, independent of sex. If you are only using a lubricant during intercourse and wondering why it does not solve the problem, this is why.
The evidence-backed options are Revaree (a hyaluronic acid vaginal insert, non-hormonal, used twice weekly) and Replens (a long-acting moisturizing gel). Both have clinical support. They work differently, for different women, and the choice between them is worth understanding. The full comparison is in the dedicated Revaree vs Replens article.
Hormonal — Local Only · Strongest Evidence Base
Vaginal Estrogen
This is not the same as systemic hormone therapy. Vaginal estrogen is applied locally, has minimal systemic absorption, and has a very different safety profile from oral or patch HRT. In November 2025, the FDA removed the boxed warning from vaginal estrogen product labels — acknowledging that the risks cited in the original warning do not apply at therapeutic doses.
Vaginal estrogen directly addresses the tissue-level changes of GSM. It rebuilds vaginal wall thickness, restores elasticity, improves lubrication, and reduces painful intercourse. Available forms include cream, tablet, suppository, and ring. The 2025 AUA/SUFU/AUGS guideline recommends it as first-line treatment for GSM.
Emerging Evidence · Off-Label in the U.S.
Testosterone for Desire
Testosterone is the primary hormonal driver of desire in women. It declines approximately 50% between ages 20 and 45, continuing through menopause. For women whose primary symptom is absent desire (not pain, not dryness), testosterone therapy has the strongest evidence base — but it remains off-label in the United States. Some compounding pharmacy options are available. Discuss with a menopause-specialist provider.
Non-Hormonal Oral · For Desire and Arousal
Bonafide Ristela
Ristela is a non-hormonal oral supplement targeting arousal and orgasm satisfaction through a vascular mechanism. It does not treat dryness or tissue atrophy — it targets the desire and arousal pathways specifically. Clinical trials showed measurable improvement at 4 weeks. For women who cannot or prefer not to use hormonal options and whose primary concern is desire rather than pain.
Pelvic floor dysfunction can compound painful sex significantly — and is treatable. The pelvic floor article covers the full protocol.
The Conversation You’ve Been Avoiding
Most partners of perimenopausal and menopausal women interpret sexual avoidance as personal rejection. They do not have a framework for understanding that pain, dryness, and neurochemical changes are driving the withdrawal — not loss of love or attraction.
The most effective way to open this conversation is to lead with biology, not behavior. Frame it as: “This is what is happening physiologically. It is not about you or about us. And I am addressing it.”
The letter framework provides the full language. The key principle: expand what intimacy means during this transition. Presence, physical touch without sexual pressure, sleeping in proximity — these are not consolation prizes. They are the foundation on which sexual connection can rebuild when the physical barriers are addressed.
The Libido Question: Is It Gone Forever?
No. Libido changes during menopause are driven by addressable physiological mechanisms, not by an irreversible switch.
Treating vaginal dryness and pain removes the physical barrier. Addressing sleep disruption reduces cortisol-mediated desire suppression. For some women, testosterone therapy restores the hormonal driver of desire. Improving the relational context through communication and emotional reconnection supports the conditions where desire arises.
One important clinical note: low desire without personal distress is not a disorder. If your libido has changed and you are comfortable with that change, there is nothing to treat. The treatment conversation is for women who are experiencing distress about their loss of desire — not for women who have simply arrived at a new baseline they are at peace with.
— Samantha